{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:42:13Z","timestamp":1781239333410,"version":"3.54.1"},"reference-count":134,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1053\/j.semnuclmed.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T23:07:42Z","timestamp":1707606462000},"page":"270-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review"],"prefix":"10.1053","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6953-1940","authenticated-orcid":false,"given":"Tasnim","family":"Khessib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-6825","authenticated-orcid":false,"given":"Guido A.","family":"Davidzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-5329","authenticated-orcid":false,"given":"Andrei","family":"Iagaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2275-9360","authenticated-orcid":false,"given":"Jagruti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0256-4947.75771","article-title":"18F-FDG PET\/CT imaging in oncology","volume":"31","author":"Almuhaideb","year":"2011","journal-title":"Ann Saudi Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.01.003_bib0002","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00259-016-3414-5","article-title":"PET\/CT is a cost-effective tool against cancer: synergy supersedes singularity","volume":"43","author":"Fischer","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0003","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2967\/jnumed.107.047787","article-title":"Recommendations on the use of 18F-FDG PET in oncology","volume":"49","author":"Fletcher","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.519440","article-title":"Diagnostic value of FDG PET\/MRI in females with pelvic malignancy\u2014A systematic review of the literature","volume":"10","author":"Nguyen","year":"2020","journal-title":"Front Oncol"},{"issue":"22","key":"10.1053\/j.semnuclmed.2024.01.003_bib0005","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.3390\/cancers14225528","article-title":"Recent Imaging updates and advances in gynecologic malignancies","volume":"14","author":"Daoud","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0006","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/cancers13030493","article-title":"GYNOCARE update: modern strategies to improve diagnosis and treatment of rare gynecologic tumors\u2014current challenges and future directions","volume":"13","author":"Di Fiore","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.01.003_bib0007","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11604-014-0317-x","article-title":"Present and future role of FDG-PET\/CT imaging in the management of gynecologic malignancies","volume":"32","author":"Kitajima","year":"2014","journal-title":"Jpn J Radiol"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0008","series-title":"Nuclear medicine manual on gynaecological cancers and other female malignancies","year":"2022"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0009","first-page":"7","article-title":"Clinical impact of 18F-FDG PET\/CT on the management of gynecologic cancers: one center experience","volume":"7","author":"Al-ibraheem","year":"2018","journal-title":"AOJNMB"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.01.003_bib0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cam4.4486","article-title":"Preoperative magnetic resonance imaging predicts clinicopathological parameters and stages of endometrial carcinomas","volume":"11","author":"Wu","year":"2022","journal-title":"Cancer Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13244-019-0696-8","article-title":"Role of MRI in staging and follow-up of endometrial and cervical cancer: Pitfalls and mimickers","volume":"10","author":"Otero-Garc\u00eda","year":"2019","journal-title":"Insights Imaging"},{"issue":"S1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ijgo.13866","article-title":"Cancer of the corpus uteri: 2021 update","volume":"155","author":"Koskas","year":"2021","journal-title":"Intl J Gynecol Obste"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0013","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Intl J Gynecol Obste"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0014","unstructured":"Gui B, Vaz SC, Russo L, et al: Radiological and Nuclear Medicine Imaging in Gynecologic Oncology. 2012;1-11"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0015","first-page":"266","article-title":"Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: Assessment by PET\/CT","volume":"45","author":"Lerman","year":"2004","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.01.003_bib0016","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1097\/IGC.0000000000000003","article-title":"Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: Systematic review and meta-analysis of the literature","volume":"23","author":"Kakhki","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"1079","key":"10.1053\/j.semnuclmed.2024.01.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170283","article-title":"The role of 18F-FDG PET CT in common gynaecological malignancies","volume":"90","author":"Narayanan","year":"2017","journal-title":"BJR"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/234813","article-title":"The preoperative maximum standardized uptake value measured by 18F-FDG PET\/CT as an independent prognostic factor of overall survival in endometrial cancer patients","volume":"2014","author":"Walentowicz-Sadlecka","year":"2014","journal-title":"BioMed Res Intern"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.01.003_bib0019","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/cancers14071779","article-title":"A Review of nuclear medicine approaches in the diagnosis and the treatment of gynecological malignancies","volume":"14","author":"Vahidfar","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.01.003_bib0020","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2967\/jnumed.115.170597","article-title":"High diagnostic value of 18 F-FDG PET\/CT in endometrial cancer: systematic review and meta-analysis of the literature","volume":"57","author":"Bollineni","year":"2016","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0021","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1148\/radiol.2016160200","article-title":"Utility of PET\/CT to evaluate retroperitoneal lymph node metastasis in high-risk endometrial cancer: Results of ACRIN 6671\/GOG 0233 trial","volume":"283","author":"Atri","year":"2017","journal-title":"Radiology"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.01.003_bib0022","first-page":"258","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"CA A Cancer J Clinicians"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0023","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1148\/radiol.2017170963","article-title":"Identification of Distant metastatic disease in uterine cervical and endometrial cancers with FDG PET\/CT: Analysis from the ACRIN 6671\/GOG 0233 multicenter trial","volume":"287","author":"Gee","year":"2018","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0024","unstructured":"National Comprehensive Cancer Network. Uterine Neoplasms (Version 1.2024). Accessed January 12, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.01.003_bib0025","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.701758","article-title":"Sentinel lymph node mapping in endometrial cancer: A comprehensive review","volume":"11","author":"Zhai","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0027","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ygyno.2019.03.254","article-title":"Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis","volume":"153","author":"Bogani","year":"2019","journal-title":"Gynecolog Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.01.003_bib0028","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ajog.2016.11.1033","article-title":"Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis","volume":"216","author":"Bodurtha Smith","year":"2017","journal-title":"Am J Obstetr Gynecol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0029","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00259-007-0627-7","article-title":"Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET","volume":"35","author":"Nishiyama","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00259-010-1614-y","article-title":"Post-treatment [18F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma","volume":"38","author":"Chung","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0031","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0032","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ygyno.2012.10.022","article-title":"Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: Systematic review and meta-analysis of the literature","volume":"128","author":"Kadkhodayan","year":"2013","journal-title":"Gynecolog Oncol"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0033","first-page":"21","article-title":"Cancer cervix: Epidemiology and disease burden","volume":"19","author":"Pimple","year":"2022","journal-title":"Cyto J"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0034","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cpet.2017.11.004","article-title":"[18F]-2-Fluoro-2-Deoxy-D-glucose\u2013PET assessment of cervical cancer","volume":"13","author":"Viswanathan","year":"2018","journal-title":"PET Clinics"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0035","unstructured":"National Comprehensive Cancer Network. Cervical Cancer (Version 1.2024). Accessed January 12, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0036","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.2147\/CMAR.S203059","article-title":"Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors","volume":"11","author":"Yan","year":"2019","journal-title":"CMAR"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0037","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ygyno.2020.08.021","article-title":"[18F]FDG-PET or PET\/CT in the evaluation of pelvic and para-aortic lymph nodes in patients with locally advanced cervical cancer: A systematic review of the literature","volume":"159","author":"Adam","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"14","key":"10.1053\/j.semnuclmed.2024.01.003_bib0038","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.ejca.2005.05.013","article-title":"Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: a prospective surgicopathologic correlation study","volume":"41","author":"Roh","year":"2005","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0039","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0090-8258(03)00058-1","article-title":"Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings","volume":"89","author":"Lin","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0135","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ygyno.2016.05.002","article-title":"Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671\/GOG0233 trial","volume":"142","author":"Atri","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.01.003_bib0040","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/cncr.22974","article-title":"The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival","volume":"110","author":"Kidd","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0041","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41824-018-0042-2","article-title":"The prognostic value of preoperative FDG-PET\/CT metabolic parameters in cervical cancer patients","volume":"2","author":"Bollineni","year":"2018","journal-title":"European J Hybrid Imaging"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0042","doi-asserted-by":"crossref","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.01.003_bib0043","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/ijgc-2023-004429","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with cervical cancer \u2013 Update 2023*","volume":"33","author":"Cibula","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0044","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ijgc-2019-001082","article-title":"Sentinel lymph node biopsy alone in the management of early cervical carcinoma","volume":"32","author":"Devaja","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0045","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00432-020-03393-6","article-title":"Sentinel lymph node mapping with indocyanine green in cervical cancer patients undergoing open radical hysterectomy: A single-institution series","volume":"147","author":"Bizzarri","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0046","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/IGC.0000000000000853","article-title":"Sentinel lymph nodes mapping in cervical cancer a comprehensive review","volume":"27","author":"Diab","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"34","key":"10.1053\/j.semnuclmed.2024.01.003_bib0047","doi-asserted-by":"crossref","first-page":"e27035","DOI":"10.1097\/MD.0000000000027035","article-title":"Sentinel lymph node mapping in early-stage cervical cancer: Meta-analysis","volume":"100","author":"Wang","year":"2021","journal-title":"Medicine"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0048","first-page":"182","article-title":"Added-value of SPECT\/CT to lymphatic mapping and sentinel lymphadenectomy in gynaecological cancers","volume":"3","author":"Belhocine","year":"2013","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0049","unstructured":"Abu-Rustum NR, Yashar CM, Arend R, et al. NCCN Guidelines Version 1.2023 Cervical Cancer. Published online January 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1102\/1470-7330.2012.0007","article-title":"The role of FDG-PET\/CT in gynaecological cancers","volume":"12","author":"Rockall","year":"2012","journal-title":"Cancer Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.01.003_bib0051","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1200\/JCO.2004.09.035","article-title":"Posttherapy [ 18 F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: Response and outcome","volume":"22","author":"Grigsby","year":"2004","journal-title":"JCO"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0052","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ygyno.2013.01.017","article-title":"The value of 18F-FDG PET\/CT in recurrent gynecologic malignancies prior to pelvic exenteration","volume":"129","author":"Burger","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0053","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MNM.0000000000000026","article-title":"Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: A systematic review and meta-analysis","volume":"35","author":"Chu","year":"2014","journal-title":"Nucl Med Commun"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0054","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4068\/cmj.2013.49.1.20","article-title":"clinical usefulness of 18 F-FDG PET\/CT in the detection of early recurrence in treated cervical cancer patients with unexplained elevation of serum tumor markers","volume":"49","author":"Chong","year":"2013","journal-title":"Chonnam Med J"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.01.003_bib0055","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3390\/diagnostics10090657","article-title":"Detection of recurrent cervical cancer and prediction of its patient survival with serum squamous-cell carcinoma-antigen and 2-[18F] Fluoro-2-Deoxy-d-glucose-positron emission tomography\/computed tomography","volume":"10","author":"Peng","year":"2020","journal-title":"Diagnostics"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.01.003_bib0056","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1016\/j.ejrad.2012.02.015","article-title":"Predictive role of post-treatment [18F]FDG PET\/CT in patients with uterine cervical cancer","volume":"81","author":"Hoon Chung","year":"2012","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0057","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13550-020-00712-3","article-title":"Diagnostic value of [18F]FDG PET\/MRI for staging in patients with ovarian cancer","volume":"10","author":"Tsuyoshi","year":"2020","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0058","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4274\/mirt.galenos.2018.00710","article-title":"The Role of 18F-FDG PET\/CT in detecting ovarian cancer recurrence in patients with elevated CA-125 Levels","volume":"28","author":"Cengiz","year":"2019","journal-title":"Mirt."},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.01.003_bib0059","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.3390\/cancers14123000","article-title":"PET-CT in clinical adult oncology\u2014IV. Gynecologic and genitourinary malignancies","volume":"14","author":"Salem","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0060","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00261-018-1779-6","article-title":"Imaging in the pre-operative staging of ovarian cancer","volume":"44","author":"Castellani","year":"2019","journal-title":"Abdom Radiol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0061","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2967\/jnumed.114.145011","article-title":"Evaluation of gynecologic cancer with MR imaging, 18 F-FDG PET\/CT, and PET\/MR imaging","volume":"56","author":"Lee","year":"2015","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0062","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2009.10.059","article-title":"Diagnosis and staging of primary ovarian cancer: correlation between PET\/CT, Doppler US, and CT or MRI","volume":"116","author":"Nam","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0063","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2006.11.022","article-title":"The diagnostic value of PET\/CT for primary ovarian cancer\u2013a prospective study","volume":"105","author":"Risum","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0064","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1148\/radiol.2233001850","article-title":"Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings","volume":"223","author":"Fenchel","year":"2002","journal-title":"Radiology"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.01.003_bib0065","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1007\/s00259-008-0890-2","article-title":"Diagnostic accuracy of integrated FDG-PET\/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT","volume":"35","author":"Kitajima","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.01.003_bib0066","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1007\/s00259-021-05450-9","volume":"48","author":"Delgado Bolton","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.01.003_bib0067","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1007\/s00259-014-2803-x","article-title":"The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET\/CT in the prognosis of epithelial ovarian cancer","volume":"41","author":"Lee","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.999749","article-title":"Where are we going with sentinel nodes mapping in ovarian cancer?","volume":"12","author":"Kampan","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.950717","article-title":"Feasibility of sentinel lymph node mapping in ovarian tumors: A systematic review and meta-analysis of the literature","volume":"9","author":"Ataei Nakhaei","year":"2022","journal-title":"Front Med"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0070","unstructured":"Armstrong DK, Alvarez RD, Backes FJ, et al. NCCN guidelines version 2.2023 Ovarian Cancer. Published online February 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf"},{"issue":"23","key":"10.1053\/j.semnuclmed.2024.01.003_bib0071","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.3390\/cancers14236010","article-title":"Cytoreductive surgery (CRS) and HIPEC for advanced ovarian cancer with peritoneal metastases: Italian PSM oncoteam evidence and study purposes","volume":"14","author":"Marrelli","year":"2022","journal-title":"Cancers"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0072","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.2967\/jnumed.108.057257","article-title":"The role of 18 F-FDG PET in assessing therapy response in cancer of the cervix and ovaries","volume":"50","author":"Schwarz","year":"2009","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.01.003_bib0073","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3390\/healthcare9060666","article-title":"A comparative study between 18F-FDG PET\/CT and Conventional imaging in the evaluation of progressive disease and recurrence in ovarian carcinoma","volume":"9","author":"Rusu","year":"2021","journal-title":"Healthcare"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0074","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2015.10.018","article-title":"18F-FDG-PET\/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"140","author":"Vallius","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0075","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s00259-015-3184-5","article-title":"Predictive value of (18)F-FDG PET\/CT in restaging patients affected by ovarian carcinoma: A multicentre study","volume":"43","author":"Caobelli","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.01.003_bib0076","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00259-020-05092-3","article-title":"Predicting tumor response and outcome of second-look surgery with 18F-FDG PET\/CT: Insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer","volume":"48","author":"Aide","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0077","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","article-title":"CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: A systematic review and meta-analysis","volume":"71","author":"Gu","year":"2009","journal-title":"Eur J Radiol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.01.003_bib0078","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MNM.0b013e32831089cb","article-title":"18F-FDG PET\/CT evaluation of patients with ovarian carcinoma","volume":"29","author":"Iagaru","year":"2008","journal-title":"Nuclear Medicine Communications"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.01.003_bib0079","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"29","author":"Colombo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.01.003_bib0080","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0081","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11604-021-01173-x","article-title":"Clinical and prognostic 18F-FDG PET\/CT role in recurrent vulvar cancer: A multicentric experience","volume":"40","author":"Albano","year":"2022","journal-title":"Jpn J Radiol"},{"issue":"38","key":"10.1053\/j.semnuclmed.2024.01.003_bib0082","doi-asserted-by":"crossref","first-page":"e7943","DOI":"10.1097\/MD.0000000000007943","article-title":"18F-FDG PET\/CT in preoperative staging of vulvar cancer patients: is it really effective?","volume":"96","author":"Crivellaro","year":"2017","journal-title":"Medicine"},{"issue":"11","key":"10.1053\/j.semnuclmed.2024.01.003_bib0083","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3390\/jpm11111219","article-title":"MRI staging in locally advanced vulvar cancer: from anatomy to clinico-radiological findings. A multidisciplinary vulcan team point of view","volume":"11","author":"Gui","year":"2021","journal-title":"JPM"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.01.003_bib0084","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00259-019-04650-8","article-title":"Lymphoscintigraphy and sentinel lymph node biopsy in vulvar carcinoma: Update from a European expert panel","volume":"47","author":"Collarino","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.01.003_bib0085","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1007\/s00259-021-05257-8","article-title":"Diagnostic performance of preoperative [18F]FDG-PET\/CT for lymph node staging in vulvar cancer: A large single-centre study","volume":"48","author":"Rufini","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0086","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/RLU.0000000000003411","article-title":"18F-FDG PET and 18F-FDG PET\/CT in vulvar cancer: A systematic review and meta-analysis","volume":"46","author":"Triumbari","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0087","series-title":"Vulvar Cancer (Version 3.2024)","year":"2024"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0088","unstructured":"Abu-Rustum NR, Yashar CM, Arend R, et al. NCCN guidelines version 1.2023 Vulvar Cancer. Published online January 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vulvar.pdf"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0089","article-title":"Sentinel lymph node mapping: Current applications and future perspectives in gynecology malignant tumors","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/ijgc-2019-000936","article-title":"Evolution and outcomes of sentinel lymph node mapping in vulvar cancer","volume":"30","author":"Broach","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0091","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ygyno.2015.06.011","article-title":"SPECT\/CT for SLN dissection in vulvar cancer: Improved SLN detection and dissection by preoperative three-dimensional anatomical localisation","volume":"138","author":"Klapdor","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.01.003_bib0092","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2007.14.0566","article-title":"Sentinel node dissection is safe in the treatment of early-stage vulvar cancer","volume":"26","author":"Van der Zee","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0093","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2015.09.077","article-title":"Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational study on sentinel nodes in vulvar cancer (GROINSS-V) I","volume":"140","author":"Te Grootenhuis","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"31","key":"10.1053\/j.semnuclmed.2024.01.003_bib0094","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1200\/JCO.2011.41.2528","article-title":"Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: A gynecologic oncology group study","volume":"30","author":"Levenback","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0095","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.radonc.2016.12.019","article-title":"Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva","volume":"122","author":"Rao","year":"2017","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0096","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1148\/rg.2017160059","article-title":"FDG PET\/CT pitfalls in gynecologic and genitourinary oncologic imaging","volume":"37","author":"Lakhani","year":"2017","journal-title":"RadioGraphics"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.01.003_bib0097","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1053\/j.semnuclmed.2021.06.006","article-title":"PET\/CT variants and pitfalls in gynecological cancers","volume":"51","author":"Dejanovic","year":"2021","journal-title":"Semin Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.01.003_bib0098","doi-asserted-by":"crossref","DOI":"10.1148\/rg.230006","article-title":"Added value of fdg pet\/mri in gynecologic oncology: A pictorial review","volume":"43","author":"Tarcha","year":"2023","journal-title":"RadioGraphics"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0099","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00259-014-2902-8","article-title":"[18F]FDG PET\/MRI vs. PET\/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results","volume":"42","author":"Beiderwellen","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.01.003_bib0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175401","article-title":"Diagnostic role of 18F-FDG PET\/MRI in patients with gynecological malignancies of the pelvis: A systematic review and meta-analysis","volume":"12","author":"Nie","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.01.003_bib0101","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MNM.0000000000000839","article-title":"Diagnostic value of 18F-FDG PET\/MRI in recurrent pelvis malignancies of female patients: A systematic review and meta-analysis","volume":"39","author":"Zheng","year":"2018","journal-title":"Nucl Med Commun"},{"issue":"8","key":"10.1053\/j.semnuclmed.2024.01.003_bib0102","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1007\/s00330-015-3657-8","article-title":"PET\/MRI and PET\/CT in advanced gynaecological tumours: Initial experience and comparison","volume":"25","author":"Queiroz","year":"2015","journal-title":"Eur Radiol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.01.003_bib0103","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1007\/s00259-021-05378-0","article-title":"68Ga-FAPI-PET\/CT in patients with various gynecological malignancies","volume":"48","author":"Dendl","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0104","doi-asserted-by":"crossref","first-page":"e92629","DOI":"10.1371\/journal.pone.0092629","article-title":"The prognostic value of CXCR4 in ovarian cancer: A meta-analysis","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.01.003_bib0105","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1172\/JCI97992","article-title":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","volume":"128","author":"Makvandi","year":"2018","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.01.003_bib0106","first-page":"1618","article-title":"Imaging of uterine carcinoma by carbon-11-methionine and PET","volume":"35","author":"Lapela","year":"1994","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0107","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/j.semnuclmed.2014.10.006","article-title":"F-18 fluoromisonidazole for imaging tumor hypoxia: Imaging the microenvironment for personalized cancer therapy","volume":"45","author":"Rajendran","year":"2015","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0108","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.gore.2015.10.003","article-title":"Pilot study assessing (18)F-fluorothymidine PET\/CT in cervical and vaginal cancers before and after external beam radiation","volume":"14","author":"Cho","year":"2015","journal-title":"Gynecol Oncol Rep"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.01.003_bib0109","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.nucmedbio.2010.12.003","article-title":"Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3\u2032deoxy-3-fluorothymidine positron emission tomography\/computed tomography imaging","volume":"38","author":"Richard","year":"2011","journal-title":"Nucl Med Biol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.01.003_bib0110","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2967\/jnumed.120.244319","article-title":"Prognostic value of 16\u03b1-18F-Fluoro-17\u03b2-Estradiol PET as a predictor of disease outcome in endometrial cancer: A prospective study","volume":"62","author":"Yamada","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0111","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2967\/jnumed.114.147579","article-title":"Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16\u03b1-18F-fluoro-17\u03b2-estradiol PET\/CT","volume":"56","author":"van Kruchten","year":"2015","journal-title":"J Nucl Med"},{"issue":"Supplement 2","key":"10.1053\/j.semnuclmed.2024.01.003_bib0112","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.2967\/jnumed.118.220566","article-title":"Future of theranostics: An outlook on precision oncology in nuclear medicine","volume":"60","author":"Langbein","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0113","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3389\/fonc.2019.01537","article-title":"Ovarian Cancer Targeted Theranostics","volume":"9","author":"Nimmagadda","year":"2019","journal-title":"Front Oncol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.01.003_bib0114","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/RLU.0000000000002612","article-title":"Predictive value of 16\u03b1-[18F]-Fluoro-17\u03b2-Estradiol PET as a biomarker of progestin therapy resistance in patients with atypical endometrial hyperplasia and low-grade endometrial cancer","volume":"44","author":"Yamada","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0115","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas Using 177Lu-FAP-2286: First-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.01.003_bib0116","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2967\/jnumed.115.167072","article-title":"Preclinical 89 Zr Immuno-PET of high-grade serous ovarian cancer and lymph node metastasis","volume":"57","author":"Sharma","year":"2016","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0117","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/gyno.1997.4870","article-title":"Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies","volume":"67","author":"Juweid","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0118","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13550-018-0437-x","article-title":"Leveraging PET to image folate receptor \u03b1 therapy of an antibody-drug conjugate","volume":"8","author":"Brand","year":"2018","journal-title":"EJNMMI Res"},{"issue":"23","key":"10.1053\/j.semnuclmed.2024.01.003_bib0119","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1158\/1078-0432.CCR-04-1226","article-title":"Targeting of HER2 antigen for the treatment of disseminated peritoneal disease","volume":"10","author":"Milenic","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.01.003_bib0120","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/COC.0000000000000353","article-title":"Safety and outcome measures of first-in-human intraperitoneal \u03b1 radioimmunotherapy with 212Pb-TCMC-trastuzumab","volume":"41","author":"Meredith","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2024.01.003_bib0121","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s10967-022-08329-7","article-title":"Preliminary evaluation and in vitro cytotoxicity studies of [131I]I-trastuzumab in HER2 expressing ovarian cancer cells","volume":"331","author":"Deng","year":"2022","journal-title":"J Radioanal Nucl Chem"},{"issue":"7","key":"10.1053\/j.semnuclmed.2024.01.003_bib0123","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/ijgc-2023-004486","article-title":"European society of gynaecological oncology guidelines for the management of patients with vulvar cancer - update 2023","volume":"33","author":"Oonk","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1053\/j.semnuclmed.2024.01.003_bib0124","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2147\/OTT.S86519","article-title":"Comparison of dynamic contrast-enhanced magnetic resonance imaging with T2-weighted imaging for preoperative staging of early endometrial carcinoma","volume":"8","author":"Zheng","year":"2015","journal-title":"OTT"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0125","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1097\/RLU.0000000000004064","article-title":"Hybrid PET\/MRI in staging endometrial cancer: Diagnostic and predictive value in a prospective cohort","volume":"47","author":"Ironi","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0126","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00259-019-04452-y","article-title":"PET\/MRI versus PET\/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations","volume":"47","author":"Mayerhoefer","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2024.01.003_bib0127","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/MNM.0000000000001257","article-title":"Synergic role of preoperative 18F-fluorodeoxyglucose PET and MRI parameters in predicting histopathological features of endometrial cancer","volume":"41","author":"Mapelli","year":"2020","journal-title":"Nucl Med Comm"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0128","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40644-020-00372-5","article-title":"Diagnostic efficiency of whole-body 18F-FDG PET\/MRI, MRI alone, and SUV and ADC values in staging of primary uterine cervical cancer","volume":"21","author":"Steiner","year":"2021","journal-title":"Cancer Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2024.01.003_bib0129","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2016.08.002","article-title":"A prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer","volume":"120","author":"Han","year":"2016","journal-title":"Radiotherapy and Oncology"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.01.003_bib0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1148\/rg.251045047","article-title":"MR imaging appearances of the female pelvis after trachelectomy","volume":"25","author":"Sahdev","year":"2005","journal-title":"RadioGraphics"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.01.003_bib0131","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1097\/SLA.0000000000005418","article-title":"Positron emission tomography\/magnetic resonance imaging (PET\/MRI) versus the standard of care imaging in the diagnosis of peritoneal carcinomatosis","volume":"277","author":"Furtado","year":"2023","journal-title":"Ann Surg"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.01.003_bib0132","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/j.semnuclmed.2015.03.005","article-title":"PET\/MRI Evaluation of gynecologic malignancies and prostate cancer","volume":"45","author":"Bagade","year":"2015","journal-title":"Semin Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2024.01.003_bib0133","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00330-014-3530-1","article-title":"Computed tomography, magnetic resonance imaging and FDG positron emission tomography in the management of vulvar malignancies","volume":"25","author":"Lin","year":"2015","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.01.003_bib0134","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00259-017-3881-3","article-title":"Comparison of 18F\u2013FDG PET\/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: A follow-up study","volume":"45","author":"Sawicki","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:42:03Z","timestamp":1757544123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299824000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":134,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0001299824000035"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.01.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}